By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sigilon 

161 First Street
Suite 2C
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-336-7540 Fax: n/a


SEARCH JOBS

Sigilon Therapeutics was founded and created by Flagship Pioneering. Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials, developed at the Massachusetts Institute of Technology (MIT), that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

YEAR FOUNDED:

June 2017

LEADERSHIP:

Scientific Founders: Bob Langer and Daniel Anderson

CEO: Paul Wotton

CTO: David Peritt, Ph.D.

CBO: James D. Watson

CAREER:

Please click here for Sigilon Therapeutics' job opportunities.

TECHNOLOGY

Please click here for Sigilon Therapeutics technology.

PIPELINE:

Please click here for Sigilon Therapeuticss pipeline.


Key Statistics


Email: info@sigilon.com
Ownership: Private

Web Site: Sigilon
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->